Evidence map›Paper›PMID 26837602›Full record

SynthesisHuman vaccines & immunotherapeutics2016

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.

Edward Gibson, Najida Begum, Birgir Sigmundsson, Alfred Sackeyfio, Judith Hackett, Sankarasubramanian Rajaram

Open access · hybridAbstract readComparative StudySystematic Review
In one paragraph

Synthesis in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Economic Evaluation in Opioid Modeling: Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Influenza vaccination: protecting the most vulnerable.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Edward Gibsona Wickenstones , Reading , UK.
Najida Beguma Wickenstones , Reading , UK.
Birgir Sigmundssona Wickenstones , Reading , UK.
Alfred Sackeyfiob AstraZeneca , Cambridge , UK.
Judith Hackettc AstraZeneca , Gaithersburg , MD , USA.
Sankarasubramanian Rajaramd AstraZeneca , Paddington , London , UK.
AstraZeneca (United Kingdom) · GBAstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study compared the economic value of pediatric immunisation programmes for influenza to those for rotavirus (RV), meningococcal disease (MD), pneumococcal disease (PD), human papillomavirus (HPV), hepatitis B (Hep B), and varicella reported in recent (2000 onwards) cost-effectiveness (CE) studies identified in a systematic review of PubMed, health technology, and vaccination databases. The systematic review yielded 51 economic evaluation studies of pediatric immunisation - 10 (20%) for influenza and 41 (80%) for the other selected diseases. The quality of the eligible articles was assessed using Drummond's checklist. Although inherent challenges and limitations exist when comparing economic evaluations of immunisation programmes, an overall comparison of the included studies demonstrated cost-effectiveness/cost saving for influenza from a European-Union-Five (EU5) and United States (US) perspective; point estimates for cost/quality-adjusted life-years (QALY) from dominance (cost-saving with more effect) to ≤45,444 were reported. The economic value of influenza programmes was comparable to the other vaccines of interest, with cost/QALY in general considerably lower than RV, Hep B, MD and PD. Independent of the perspective and type of analysis, the economic impact of a pediatric influenza immunisation program was influenced by vaccine efficacy, immunisation coverage, costs, and most significantly by herd immunity. This review suggests that pediatric influenza immunisation may offer a cost effective strategy when compared with HPV and varicella and possibly more value compared with other childhood vaccines (RV, Hep B, MD and PD).

Indexed as

AdolescentChickenpox VaccineChildChild, PreschoolCost-Benefit AnalysisEuropeFemaleHepatitis B VaccinesHumansImmunity, HerdImmunization ProgramsInfantInfluenza, HumanInfluenza VaccinesMaleMeningococcal VaccinesChickenpox VaccineHepatitis B VaccinesInfluenza VaccinesMeningococcal VaccinesPapillomavirus VaccinesPneumococcal VaccinesRotavirus Vaccinescost-effectivenesseconomic evaluationinfluenzapediatric immunisation programvaccines

Identifiers

PMID26837602
PMCPMC4963059
OpenAlexW2330193063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.